Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Strategic window drives Microcide

Until now, antibiotics have been the terrain of the pharmaceutical giants, a terrain they have dominated by developing successive generations of broad spectrum antibiotics.

But like all large organizations, pharmaceutical companies tend to ignore business opportunities that can't meet their high hurdles for market size. As a result, they may miss chances to enter new research areas.

Start-up Microcide Inc. is challenging that dominance with an opportunistic strategy aimed at showing not only that a biotech company can move faster

Read the full 788 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE